Header
Header
Article

P052 REAL WORLD EXPERIENCE IN THERAPEUTIC DRUG MONITORING IN INFLAMMATORY BOWEL DISEASE PATIENTS ON VEDOLIZUMAB



Current evidence supports the use of reactive therapeutic drug monitoring (TDM) to guide treatment changes in inflammatory bowel disease (IBD) patients treated with anti-TNF agents. However, there is less data available on the utility of drug monitoring with vedolizumab (VDZ).

Source link

Back to top button